Comparison of M-Vax Plus Low Dose Interleukin-2 Versus Placebo Vaccine Plus Low Dose Interleukin-2 in Patients With Stage IV Melanoma.

Trial Profile

Comparison of M-Vax Plus Low Dose Interleukin-2 Versus Placebo Vaccine Plus Low Dose Interleukin-2 in Patients With Stage IV Melanoma.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs BCG; Cyclophosphamide; Interleukin-2; Melanoma vaccine DNP-VACC
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms MVALDI
  • Most Recent Events

    • 02 Dec 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2021 as reported by ClinicalTrials.gov.
    • 02 Dec 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2019 as reported by ClinicalTrials.gov.
    • 02 Dec 2015 Status changed from active, no longer recruiting to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top